Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Awaiting development [GID-TA10605] Expected publication date: TBC
Search results
221 results
-
-
Remdesivir for treating COVID-19 [ID3808]
Awaiting development [GID-TA10721] Expected publication date: TBC
-
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154
Awaiting development [GID-TA10198] Expected publication date: TBC
-
Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Awaiting development [GID-TA10657] Expected publication date: TBC
-
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development [GID-TA10431] Expected publication date: TBC
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
Semaglutide for treating type 2 diabetes (ID1450)
Awaiting development [GID-TA10438] Expected publication date: TBC
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]
Awaiting development [GID-TA10655] Expected publication date: TBC
-
Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]
Awaiting development [GID-TA10336] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
-
Tocilizumab for treating systemic sclerosis (ID1396)
Awaiting development [GID-TA10346] Expected publication date: TBC
-
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Awaiting development [GID-TA10453] Expected publication date: TBC
-
Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]
Awaiting development [GID-TA10777] Expected publication date: TBC
-
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940
Awaiting development [GID-TA10830] Expected publication date: TBC
-
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943
Awaiting development [GID-TA10831] Expected publication date: TBC
-
Mavorixafor for treating WHIM syndrome ID3946
Awaiting development [GID-TA10833] Expected publication date: TBC
-
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]
Awaiting development [GID-TA10752] Expected publication date: TBC
-
Intravenous zanamivir for treating influenza in hospital [ID1196]
Awaiting development [GID-TA10298] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Awaiting development [GID-TA10700] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development [GID-TA10774] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development [GID-TA10776] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development [GID-TA10604] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development [GID-TA10638] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Awaiting development [GID-TA10679] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Awaiting development [GID-TA10684] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Awaiting development [GID-TA10685] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development [GID-TA10553] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Awaiting development [GID-TA10783] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Awaiting development [GID-TA10787] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Awaiting development [GID-TA10791] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Awaiting development [GID-TA10797] Expected publication date: TBC
-
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Awaiting development [GID-TA10800] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Awaiting development [GID-TA10811] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Awaiting development [GID-TA10813] Expected publication date: TBC
-
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development [GID-TA10823] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Awaiting development [GID-TA10826] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Awaiting development [GID-TA10722] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Awaiting development [GID-TA10818] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Awaiting development [GID-TA10662] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Awaiting development [GID-TA10665] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development [GID-TA10694] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Awaiting development [GID-TA10574] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Awaiting development [GID-TA10715] Expected publication date: TBC
-
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development [GID-TA10717] Expected publication date: TBC
-
Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID 5081]
Awaiting development [GID-TA10963] Expected publication date: TBC
-
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]
Awaiting development [GID-TA10995] Expected publication date: TBC